RPS6KA1 and lung carcinoma: Our work revealed that miR-486-5p could hinder lung cancer tumorigenesis through inhibition and inactivation of the mTOR pathway by targeting RSK and p70S6K, and the miR-486-5p/RSK/mTORC1/p70S6K axis (Figure 7) could be active.